Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Decreased by Harvey Capital Management Inc.

Key Points

• Harvey Capital Management cut its Regeneron stake by 50.1% in the second quarter, selling 5,001 shares and retaining 4,975 shares valued at $3.1 million. Institutional investors collectively own 83.31% of REGN.
• Regeneron reported strong quarterly results, with EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion, up 16.7% year over year. The company also declared a quarterly dividend of $0.94 per share.
• The FDA’s approval of Pasatru expands Regeneron’s rare-disease portfolio, but mixed melanoma-trial results and related securities litigation create pipeline, legal and disclosure risks; analysts maintain a “Moderate Buy” consensus rating.

Harvey Capital Management Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 50.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,975 shares of the biopharmaceutical company's stock after selling 5,001 shares during the quarter. Harvey Capital Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $3,102,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at about $26,000. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $26,000. Titan Wealth CI Ltd bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $29,000. Kemnay Advisory Services Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Finally, Birchwood Financial Partners Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $32,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 0.9%

NASDAQ:REGN opened at $807.71 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $847.00. The firm has a market capitalization of $83.16 billion, a P/E ratio of 19.96, a P/E/G ratio of 1.39 and a beta of 0.22. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The business has a 50 day simple moving average of $713.83 and a 200 day simple moving average of $717.85.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the prior year, the business earned $12.81 EPS. The firm's revenue was up 16.7% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.29%.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone formation and progressive loss of movement. Approval gives Regeneron a new commercial product and strengthens its rare-disease portfolio. However, the small patient population may limit its immediate contribution to earnings. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: A Sound Shore Management investor letter highlighted Regeneron’s need to adjust its strategy following mixed results in melanoma drug trials. The commentary reflects ongoing investor debate about the company’s pipeline and long-term growth, while other market coverage indicates Wall Street remains reasonably constructive on the broader outlook. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Multiple law firms announced or promoted a securities class action concerning allegations that Regeneron misled investors about the prospects of the Phase 3 Fianlimab-Libtayo trial for advanced melanoma. The trial failure reportedly caused a major selloff and an approximately $11 billion decline in market capitalization. The allegations have not been proven, but the litigation adds reputational, legal, and disclosure risk; the lead-plaintiff deadline is September 14, 2026. Regeneron Investors Have Opportunity to Lead Class Action Lawsuit

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a report on Thursday, July 9th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 15th. Canaccord Genuity Group decreased their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating for the company in a report on Tuesday, May 19th. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating for the company in a research note on Thursday, April 30th. Finally, BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a report on Monday, May 18th. Fifteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $800.36.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company's stock, valued at $1,362,400. The trade was a 31.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director owned 603 shares of the company's stock, valued at approximately $482,400. This trade represents a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock valued at $1,090,030 in the last quarter. Company insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source